PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

lamotrigine Side Effects

The reactions most often reported to the FDA for lamotrigine (also sold as Lamictal), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

127,196
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2002 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of lamotrigine come from 127,196 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 127,196 reports to the FDA Adverse Event Reporting System (FAERS) for lamotrigine (Lamictal): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

127,196

Reports Mentioning Death

10,680

8.4% of reports — not proof the medicine caused the death

Hospitalizations

38,667

30.4% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

RASH
8,408
SEIZURE
6,527
NAUSEA
6,149
FATIGUE
5,915
DIZZINESS
5,770
HEADACHE
5,563
DEPRESSION
4,954
VOMITING
4,544
PYREXIA
4,357
SOMNOLENCE
4,334
ANXIETY
4,321
DRUG INTERACTION
4,297
TOXICITY TO VARIOUS AGENTS
4,077
INSOMNIA
3,753
CONVULSION
3,674
PAIN
3,583
FALL
3,564
CONDITION AGGRAVATED
3,561

Who Reports Side Effects

Gender Distribution

Female 75,506 (68%)
Male 35,158 (32%)
Unknown 535

Age Distribution

0-17 9,914 (12%)
18-44 35,619 (45%)
45-64 24,403 (31%)
65-74 6,535 (8%)
75+ 3,418 (4%)

Reporting Trend by Year

2002 2025

Reactions in Death Reports

Top reactions reported in 10,680 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
COMPLETED SUICIDE 3,161
TOXICITY TO VARIOUS AGENTS 1,790
DEATH 1,531
GENERAL PHYSICAL HEALTH DETERIORATION 835
MATERNAL EXPOSURE DURING PREGNANCY 823
RASH 770
PEMPHIGUS 741
TYPE 2 DIABETES MELLITUS 736
SYSTEMIC LUPUS ERYTHEMATOSUS 733
CONFUSIONAL STATE 721
PERICARDITIS 713
CARDIO-RESPIRATORY ARREST 711
CARDIAC ARREST 709
SYNOVITIS 708
GLOSSODYNIA 686
HYPERTENSION 677
PAIN 674
EPILEPSY 672

Reactions in Hospitalization Reports

Top reactions in 38,667 reports where hospitalization was an outcome.

Reaction Reports
RASH 3,158
PYREXIA 2,977
VOMITING 2,296
NAUSEA 2,232
SEIZURE 2,209
DIZZINESS 2,011
TOXICITY TO VARIOUS AGENTS 1,979
FATIGUE 1,960
HEADACHE 1,934
FALL 1,910
DEPRESSION 1,866
CONFUSIONAL STATE 1,798
DRUG INTERACTION 1,769
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS 1,727
STEVENS-JOHNSON SYNDROME 1,697
INTENTIONAL OVERDOSE 1,669
OVERDOSE 1,623
SOMNOLENCE 1,612

Compare lamotrigine vs brivaracetam →

What the FAERS Data Reveals About lamotrigine Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 127,196 voluntary reports linked to lamotrigine and its brand equivalents (Lamictal), spanning 2002 through 2025. Of those, 10,680 (8.4%) listed death as an outcome and 38,667 (30.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 68% were female and 32% male; age distribution skews toward 18-44, with 35,619 reports in that bracket. The single most reported reaction is rash with 8,408 submissions, followed by seizure and nausea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.